Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Spirit Scientific Co., Ltd. (7790:TWSE), powered by AI.
Spirit Scientific Co., Ltd. is currently trading at $49.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Spirit Scientific Co., Ltd. on Alpha Lenz.
View Spirit Scientific Co., Ltd.'s valuation metrics on Alpha Lenz.
“Spirit Scientific Co., Ltd.'s ROE is 5.4%. Explore profitability and growth together.”
Ask for details →Spirit Scientific Co., Ltd. is a biotechnology company specializing in the development and commercialization of advanced regenerative medical technologies. Its core focus lies in providing platelet-lyophilized technology and autologous regenerative reagent preparation services, notably for applications in orthopedics and pain management. The company offers innovative products such as Vessel-X—a bone filling system for spinal compression fractures—as well as platelet-based therapeutic solutions targeting osteoarthritis and sports injuries. By harnessing patented platelet-lyophilization processes, Spirit Scientific enables the production of high-purity, shelf-stable platelet preparations intended for personalized medicine. Additional services include clinical research collaboration, blood component manufacturing, and consultancy on biomaterial laboratory construction. The company operates a dedicated biotechnology laboratory, emphasizing the standardization and scalability of its proprietary processes. Spirit Scientific plays a prominent role in Taiwan’s biotechnology and medical research sector, supporting the advancement of minimally invasive treatments and contributing to the growing field of regenerative therapies in healthcare.
“Spirit Scientific Co., Ltd.'s ROE is 5.4%. Explore profitability and growth together.”
Ask for details →Spirit Scientific Co., Ltd. (ticker: 7790) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 98 employees.
The current price is 49 with a P/E ratio of -x and P/B of -x.
ROE is 5.37% and operating margin is 8.17%. Annual revenue is $273M.